ConductScience.org, home

Paper41468356

Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.

Deshmukh MS and 8 others. Cancer Prev Res (Phila), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ. Papers, record 41468356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41468356

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.
PubMed
Journal
Cancer Prev Res (Phila)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-20
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
TamoxifenMajor topic
Breast NeoplasmsMajor topic
Carcinoma, Intraductal, NoninfiltratingMajor topic
Antineoplastic Agents, HormonalMajor topic
Carcinoma, LobularMajor topic
Humans
Female
Middle Aged
Aged
Hyperplasia
Adult
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Retrospective Studies
Follow-Up Studies

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA013696NCI NIH HHSUnited StatesP30CA013696PubMedNIH RePORTER
R01 CA226060NCI NIH HHSUnited StatesR01CA226060PubMedNIH RePORTER
R01 CA293927NCI NIH HHSUnited StatesR01CA293927PubMedNIH RePORTER
UL1 TR000040NCATS NIH HHSUnited StatesUL1TR000040PubMedNIH RePORTER
R01CA293927National Cancer Institute (NCI)R01CA293927PubMedNIH RePORTER
R01CA226060National Cancer Institute (NCI)R01CA226060PubMedNIH RePORTER
P30CA013696National Cancer Institute (NCI)P30CA013696PubMedNIH RePORTER
UL1TR000040National Center for Advancing Translational Sciences (NCATS)UL1TR000040PubMedNIH RePORTER

Download CSV of grants

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19747868Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst1998https://conductscience.org/library/papers/9747868PubMed
221537936Second events following ductal carcinoma in situ of the breast: a register-based cohort study.Breast Cancer Res Treat2011https://conductscience.org/library/papers/21537936PubMed
339837695Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience.Clin Breast Cancer2025https://conductscience.org/library/papers/39837695PubMed
439623980Selecting the Right Dose to Move Breast Cancer Prevention Forward.Cancer Prev Res (Phila)2024https://conductscience.org/library/papers/39623980PubMed
520458026Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.J Clin Oncol2010https://conductscience.org/library/papers/20458026PubMed
630815800Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor.Ann Surg Oncol2019https://conductscience.org/library/papers/30815800PubMed
726615179Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.J Natl Cancer Inst2016https://conductscience.org/library/papers/26615179PubMed
835378642Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.Breast Cancer Res Treat2022https://conductscience.org/library/papers/35378642PubMed
931479306Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.J Clin Oncol2019https://conductscience.org/library/papers/31479306PubMed
1038704119Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial.Contemp Clin Trials2024https://conductscience.org/library/papers/38704119PubMed
1129061559A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene.Cancer Prev Res (Phila)2018https://conductscience.org/library/papers/29061559PubMed
1225993215Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.Am Soc Clin Oncol Educ Book2015https://conductscience.org/library/papers/25993215PubMed
1333863327Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women's risk-reduction experiences.BMC Womens Health2021https://conductscience.org/library/papers/33863327PubMed
1439377401Improved Uptake and Adherence to Risk-Reducing Medication with the Use of Low-Dose Tamoxifen in Patients at High Risk for Breast Cancer.Cancer Prev Res (Phila)2024https://conductscience.org/library/papers/39377401PubMed
1528611039Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.Cancer Prev Res (Phila)2017https://conductscience.org/library/papers/28611039PubMed
1616110014Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.J Clin Oncol2005https://conductscience.org/library/papers/16110014PubMed
1730973790Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.J Clin Oncol2019https://conductscience.org/library/papers/30973790PubMed
1827381855Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.Int J Cancer2016https://conductscience.org/library/papers/27381855PubMed
1936095296Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.J Clin Oncol2022https://conductscience.org/library/papers/36095296PubMed
2036917758Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.J Clin Oncol2023https://conductscience.org/library/papers/36917758PubMed

See all 22 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42391096Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.J Natl Cancer Inst2026https://conductscience.org/library/papers/42391096

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41468356

GET https://conductscience.org/api/papers/v1/41468356/references?page=2